Impax Laboratories (NASDAQ: IPXL) reported Q2 EPS of $0.34, $0.01 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $214.2 million versus the consensus estimate of $199.93 million.

For earnings history and earnings-related data on Impax Laboratories (IPXL) click here.